Treatment With Intent to Generate Endovascular Reperfusion



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 85
Updated:3/7/2019
Start Date:May 9, 2018
End Date:May 2020
Contact:Walid Haddad, Ph.D
Email:walid@rapid-medical.com
Phone:+972545942299

Use our guide to learn which trials are right for you!

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood
flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic
stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail
IV t-PA therapy are candidates for treatment.

The objective of the TIGER Study is to evaluate the safety and effectiveness of the
Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in
patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is
designed to support substantial equivalence to approved and marketed products such as the
Solitaire or Trevo Retriever.


Inclusion Criteria:

1. New focal neurologic deficit consistent with being of acute cerebral ischemia origin.

2. Age 18-85 years old (inclusive).

3. Interventionalist estimates that treatment with the Tigertriever (first deployment in
target vessel) can be achieved within 8 hours of symptom onset.

4. Patient either: a) eligible for, and received, IV t-PA within 3 hours of symptom
onset, at the correct 0.9 mg/kg dose, or b) ineligible for IV t-PA.

5. NIH Stroke Scale score of 8-29.

6. No known significant pre-stroke disability (prestroke mRS 0 or 1).

7. Catheter angiographic confirmation of a large vessel occlusion in the intracranial
internal carotid artery, the M1 or M2 segments of the middle cerebral artery, the
intracranial vertebral artery, or the basilar artery that is accessible to
Tigertriever device.

8. For strokes in the anterior circulation, the following imaging criteria should also be
met:

1. MRI criterion: volume of diffusion restriction visually assessed ≤50 mL, OR

2. CT criterion: ASPECTS 6 to 10 on baseline NCCT or CTA-source images,

9. For strokes in the posterior circulation, the following imaging criterion should also
be met: pcASPECTS score 8 to 10 on baseline NCCT, CTA-source images, or DWI MRI.

10. Anticipated life expectancy of at least 6 months.

11. A signed informed consent by patient or a Legally Authorized Representative or
independent physician in case of oral consent.

Exclusion Criteria:

1. Subject already participating in another study of an investigational treatment device
or treatment.

2. Use of any other intra-arterial recanalization drug or device prior to the
Tigertriever (Tigertriever not as first choice device).

3. Angiographically evident excessive arterial tortuosity precluding device access to the
thrombus.

4. For all patients, severe sustained hypertension with SBP >220 and/or DBP >120; for
patients treated with IV tPA, sustained hypertension despite treatment with SBP >185
and/or DBP > 110.

5. Glucose < 50 mg/dl (2.78 mmol/L) or > 400 mg/dl (22.20 mmol/L).

6. Known hemorrhagic diathesis.

7. Coagulation factor deficiency or oral anti-coagulant therapy with an international
normalized ratio (INR) of more than 3.0.

8. Treatment with heparin within 48 h with a partial thromboplastin time more than two
times the laboratory normal.

9. Patients who have received a direct thrombin inhibitor within the last 48 hours; must
have a partial thromboplastin time (PTT) less than 1.5 times the normal to be
eligible.

10. Platelet count of less than 50,000/uL.

11. History of severe allergy to contrast medium, nickel, or Nitinol.

12. Intracranial hemorrhage.

13. Significant mass effect with midline shift.

14. Intracranial tumor (apart from small meningioma, ≤ 2 cm in diameter).

15. Stenosis or any occlusion in the deployment site or in a proximal vessel requiring
treatment or preventing device access to the thrombus (for example, stenosis or
occlusion in the cervical internal carotid artery).

16. Females who are pregnant or breastfeeding.

17. Known current use of cocaine at time of treatment.

18. Prior recent stroke in the past 3 months.

19. Renal failure with serum creatinine >3.0 or Glomerular Filtration Rate (GFR) <30.

20. Known cerebral vasculitis.

21. Rapidly improving neurological status defined as improvement of greater than 8 points
on the NIHSS or improvement to NIHSS of < 6 prior to procedure

22. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.

23. Ongoing seizure due to stroke.

24. Evidence of active systemic infection.

25. Known cancer with metastases.

26. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis.

27. Evidence of dissection in the extra or intracranial cerebral arteries.

28. Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or
anterior/posterior circulation).

29. Aneurysm in target vessel.
We found this trial at
11
sites
4802 10th Ave
Brooklyn, New York 11219
(718) 283-6000
Principal Investigator: Erez Nossek, MD
Phone: 718-283-7927
Maimonides Medical Center At 103 years old, Maimonides Medical Center remains a vital and thriving...
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
Principal Investigator: Dileep Yavagal, MD
Phone: 305-243-1129
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Hormozd Bozorgchami, MD
Phone: 503-494-7222
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Buffalo, New York 14215
Principal Investigator: Kenneth Snyder, MD
Phone: 716-929-9643
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Ronald F. Budzik, MD
Phone: 614-566-1255
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Harlingen, Texas 78550
Principal Investigator: Ameer Hassan, MD
Phone: 956-491-9622
?
mi
from
Harlingen, TX
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Ricardo Hanel, MD
Phone: 904-202-7089
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Marietta, Georgia 30060
Principal Investigator: Rishi Gupta, M.D
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Miami, Florida 33183
Principal Investigator: Guilherme Dabus, MD
Phone: 786-596-5972
?
mi
from
Miami, FL
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Bradley Gross, MD
Phone: (412) 647-1618
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Toledo, Ohio 43604
Principal Investigator: Osama O Zaidat, MD
Phone: 419-251-8468
?
mi
from
Toledo, OH
Click here to add this to my saved trials